



PATENT
Serial No. 08/215,007
Attorney Docket No. 0085.005

I hereby certify that this paper is being deposited in the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on December 22, 1994.

Barbara G. McClung

Date

Reg. No. 33,113

#29
Decl. w/attach
1-6-95

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: VAN NEST, et al.

Serial No.: 08/215,007

Group: 1811

Filed: March 21, 1994

Examiner: C. Salata

For: ADJUVANT FORMULATION COMPRISING
A SUBMICRON OIL DROPLET EMULSION

DECLARATION UNDER 37 C.F.R. 1.132

RECEIVED
JAN 22 1994
GHOOR 1000

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

1. We, Gary A. Van Nest, of 4890 San Pablo Dam Road, El Sobrante, California, and Gary Ott, of 112 Marlow Drive, Oakland, California, and Gail L. Barchfeld, of 2225 Romey Lane, Hayward, California, do swear that we are co-inventors of the above-captioned patent application, Serial No. 08/215,007.

2. Furthermore, we have read the Office Action, dated June 27, 1994, and are familiar with Cantrell, et al., U.S. 4,803,070, and Glass, et al., U.S. 3,919,411.

3. In our laboratories, we performed the experiments summarized in Figure 1 hereto. These animal studies showed the effect on mean antibody titers of various adjuvants combined with HIV gp120 antigen. Specifically, the following adjuvants were tested in baboons: alum (a suspension of aluminum hydroxide particles in water and the only adjuvant approved for human use), a Cantrell oil-in-water emulsion obtained from Ribi ImmunoChem Research Inc., and two of our submicron oil-in water emulsions. As can be seen, the submicron emulsions generated unexpectedly higher antibody titers.


4. After the Examiners' Interview on June 2, 1994, we undertook to determine the size of the oil droplets obtained by following the method described in Cantrell, et al., U.S. 4,803,070. Our procedure was as follows: 10 mg Ribi monophosphoryl lipid A (MPL referred to as refined detoxified endotoxin in U.S. 4,803,070) was dissolved in 1 ml 4:1 chloroform/methanol and 0.5 ml was transferred to a 15 ml Wheaton glass dounce homogenizer. 10 mg trehalose dimycolate (TDM) was dissolved in 1 ml 4:1 chloroform:methanol which was combined with the MPL solution in the dounce. Solvent was blown off with a stream of dry nitrogen. 2 ml squalene (Sigma) was added to the dounce dissolving the MPL and TDM. 98 ml of 0.2% Tween 80 was made by stirring 0.2 ml Tween into 98 ml PBS (0.15 M NaCl, .1 M sodium phosphate pH=7.4). 10 ml of 0.25 Tween was added to the dounce and a pre-emulsion made by five passes of a Type A (tight-fitting) pestle. The pre-emulsion was combined with the remaining 0.2% Tween 80 and transferred to a 100 ml homogenizing cylinder which was fitted to the Yamato LH21 homogenizer. The emulsion was homogenized with the Teflon pestle supplied by the manufacturer at 100 RPM for five minutes. Emulsion size was determined by laser light-scattering in the Malvern Mastersizer X using the lens system suitable for size determination in the 0.1-80 u range.

5. The Ribi emulsion (Cantrell) had a volume averaged mean diameter of 22.4 u (see D[4 3] on the chart, see Figure 2a. A control submicron oil-in-water emulsion of ours had a volume averaged mean diameter of .36 u, see Figure 2b. Thus, the emulsion described by Cantrell is significantly larger than our claimed submicron emulsions.


PATENT
Serial No. 08/215,007
Attorney Docket No. 0085.005

6. We declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereof.

Date: 12/22/94


Gary A. Van Nest


Date: 12/27/94


Gary Ott

Date: 12/22/94


Gail L. Barchfeld

FIGURE 1
**EFFECT OF DIFFERENT ADJUVANTS
 WITH HIV gp120 VACCINE IN BABOONS**



Groups of five baboons were immunized three times (at week 0, week 8, and week 24) with 50 µg of gp120 and the different adjuvants. Two weeks after the second and third immunizations, animals were bled and anti-gp120 antibody titers were determined by ELISA. The values expressed are the geometric means titers ± standard error for the adjuvant groups. The adjuvants used include alum (aluminum hydroxide), squalene/Tween 80/monophosphoryl lipid A (Cantrell formulation prepared by Ribi Immunochem, Inc.), MF59 (microfluidized emulsion containing 5% squalene, 0.5% Tween 80, and 0.5% Span 80), and MF59/MTP-PE (microfluidized emulsion containing 5% squalene, 0.5% Tween 80, 0.5% Span 85 and 50µg MTP-PE).

Figure 2a

MAVERIN MASTERSIZER X

Version 1.2b

Wed, Aug 03, 1994 9:39AM

Gary's RIBI :Run Number 1

8/3/94

Sample File Name: TEST Record: 143

Source: Analysed

Measured on: Wed, Aug 03, 1994 9:39AM Last saved on: Wed, Aug 03, 1994 9:39AM

Presentation: 2OHD
 Very Polydisperse model

Volume Result

Focus = 45 mm.

Residual = 0.462 %

Concentration = 0.009 %

Obscuration = 14.75 %

 $d(0.5) = 17.75 \mu\text{m}$ $d(0.1) = 1.17 \mu\text{m}$ $d(0.9) = 54.09 \mu\text{m}$ $D[4, 3] = 22.41 \mu\text{m}$

Span = 2.98

Mode = 29.89 μm Sauter Mean ($D[3,2]$) = 3.40 μm

Specific Surface Area = 1.7656 sq. m. / gm

Density = 1.00 gm. / c.c.

Size (Lo) μm	Result In %	Size (Hi) μm	Result Below %
0.05	0.03	0.12	0.03
0.12	0.05	0.15	0.08
0.15	0.08	0.19	0.16
0.19	0.15	0.23	0.32
0.23	0.25	0.28	0.57
0.28	0.40	0.35	0.97
0.35	0.60	0.43	1.57
0.43	0.89	0.53	2.46
0.53	1.27	0.65	3.72
0.65	1.75	0.81	5.47
0.81	2.33	1.00	7.81
1.00	2.95	1.23	10.76
1.23	3.39	1.51	14.14
1.51	3.45	1.86	17.59
1.86	3.07	2.30	20.66
2.30	2.52	2.83	23.18

Size (Lo) μm	Result In %	Size (Hi) μm	Result Below %
2.83	2.02	3.49	25.19
3.49	1.75	4.30	26.94
4.30	1.66	5.29	28.60
5.29	1.81	6.52	30.42
6.52	2.16	8.04	32.57
8.04	2.88	9.91	35.45
9.91	3.87	12.21	39.32
12.21	5.45	15.04	44.77
15.04	6.75	18.54	51.52
18.54	7.86	22.84	59.38
22.84	7.94	28.15	67.32
28.15	7.96	34.69	75.28
34.69	7.30	42.75	82.58
42.75	6.64	52.68	89.22
52.68	5.71	64.92	94.94
64.92	5.06	80.00	100.00




Figure 2b



MAVERIN MASTERSIZER X

Version 1.2b

Wed, Aug 03, 1994 9:52AM

MF59-0, bottle 2 :Run Number 3

8/3/94

Sample File Name: TEST , Record: 145
 Measured on: Wed, Aug 03, 1994 9:52AM Last saved on: Wed, Aug 03, 1994 9:52AM

Source: Analysed

Presentation: 2OHD
 Very Polydisperse model

Volume Result

Focus = 45 mm.

Residual = 2.325 %

Concentration = 0.002 %

Obscuration = 13.71 %

 $d(0.5) = 0.33 \mu\text{m}$ $d(0.1) = 0.19 \mu\text{m}$ $d(0.9) = 0.56 \mu\text{m}$ $D[4,3] = 0.36 \mu\text{m}$

Span = 1.13

Mode = 0.32 μm Sauter Mean ($D[3,2]$) = 0.30 μm

Density = 1.00 gm. / c.c.

Specific Surface Area = 20.1342 sq. m. / gm

Size (Lo) μm	Result In %	Size (Hi) μm	Result Below %
0.05	0.85	0.12	0.85
0.12	1.33	0.15	2.18
0.15	6.87	0.19	9.05
0.19	11.70	0.23	20.75
0.23	16.45	0.28	37.20
0.28	19.25	0.35	56.45
0.35	17.91	0.43	74.36
0.43	13.33	0.53	87.69
0.53	7.69	0.65	95.38
0.65	3.19	0.81	98.57
0.81	0.98	1.00	99.55
1.00	0.27	1.23	99.82
1.23	0.09	1.51	99.91
1.51	0.04	1.86	99.95
1.86	0.02	2.30	99.97
2.30	0.01	2.83	99.98

Size (Lo) μm	Result In %	Size (Hi) μm	Result Below %
2.83	0.01	3.49	99.99
3.49	0.01	4.30	99.99
4.30	0.00	5.29	100.00
5.29	0.00	6.52	100.00
6.52	0.00	8.04	100.00
8.04	0.00	9.91	100.00
9.91	0.00	12.21	100.00
12.21	0.00	15.04	100.00
15.04	0.00	18.54	100.00
18.54	0.00	22.84	100.00
22.84	0.00	28.15	100.00
28.15	0.00	34.69	100.00
34.69	0.00	42.75	100.00
42.75	0.00	52.68	100.00
52.68	0.00	64.92	100.00
64.92	0.00	80.00	100.00

